Dey DuoNeb

Albuterol and ipratropium dual-therapy nebulizer is approved for "the treatment of bronchospasm associated with chronic obstructive pulmonary disease in patients requiring more than one bronchodilator." FDA approved the inhalation solution of 3.0 mg albuterol and .5 mg ipratropium/3 mL March 21. A 12-week, 863-patient trial comparing DuoNeb with albuterol and ipratropium alone demonstrated that DuoNeb contributed to the improvement in pulmonary function "especially during the first 4 to 5 hours after dosing and that DuoNeb was significantly more effective than albuterol sulfate or ipratropium bromide alone," labeling states